at Benzinga.com (Jan 12, 2015)
Jazz Pharmaceuticals (JAZZ) gains 3.1% AH after guiding for 2012 revenue of $465M-$490M and EPS of $4-$4.15, above a consensus of $462.8M and $3.40. The guidance takes into account Jazz's planned merger with Azur Pharma, which the companies hope to close on Jan. 16 - it's possible not all analyst forecasts took the deal into account.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at MarketWatch.com (Jan 8, 2015)
at Investor's Business Daily (Dec 15, 2014)
at Zacks.com (Dec 15, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs